Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.55 USD
−159.72 M USD
0.00 USD
55.03 M
About ABIVAX
Sector
CEO
Marc M. P. de Garidel
Headquarters
Paris
Website
Founded
2013
FIGI
BBG01JLQNZ03
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.